Conducting a CAR-T Trial: A Pediatric Rheumatologist’s Reflections Save
At the American College of Rheumatology (ACR) Convergence 2026 meeting, a scientific session titled “Program and Ethical Readiness in Pediatric Rheumatology: Building CAR Therapy Pathways for Rare Disease Care” addressed our readiness as a field for CAR based therapies. During this session, Dr. Hermine Brunner discussed the ethical and logistic considerations involved in bringing these therapies into clinical practice. With rapid advances in CAR-T and related approaches in rheumatology, cellular therapies are likely to become a crucial part of our landscape.
However, translating the scientific advances into operational clinical trials requires far more than identifying eligible patients. It demands extensive interdisciplinary collaboration, institutional commitment, operational infrastructure and dedicated time and personnel. Not every academic center, let alone a smaller pediatric rheumatology program is equipped to undertake such trials.
As a mid-career pediatric rheumatologist and the sole one at my center in Louisiana, leading a Phase 1 CAR-T trial for lupus has been an extraordinary learning experience. I share my reflections and perspective in the hope that it may be helpful to colleagues venturing into this increasingly familiar territory.
My greatest strength and motivation have always been the patient population that I serve. Many children and adolescents with lupus in Louisiana have severe, treatment-refractory disease, face substantial socioeconomic challenges and barriers to healthcare access, and belong to populations historically underrepresented in clinical trials. Ensuring that children in our region have access to emerging, cutting-edge treatment options, rather than being excluded by geography, is what led me, not a clinical trialist, to venture into this territory. However, I quickly learned that enthusiasm and passion alone do not translate into trial readiness.
Before committing to the trial, the first and most crucial conversation I had was with our Oncology/Bone Marrow transplantation (BMT) colleagues. To my surprise and delight, their answer was an almost immediate and reassuring “yes”. I recognize how fortunate I am to work with the head of our BMT program, who is not only a colleague seasoned in CAR-T trials in oncology, but is also an exceptionally knowledgeable, kind and supportive individual and friend. Additionally, the program has an existing foundation of necessary accreditations, infrastructure and a highly skilled team that makes conducting such a trial possible.
Dr. Brunner’s presentation outlined a workflow for CAR-based therapies, beginning with pre-infusion screening, disease activity assessments and adjustment to immunomodulatory therapies; progressing through conditioning and cellular infusion; and continuing into intensive post-infusion monitoring. Although this blueprint appears straightforward, the implementation demands very close collaboration between teams. Rheumatologists bring expertise in disease phenotype, activity assessment and management, ensuring that the appropriate patients are carefully evaluated for trial participation. The BMT team contributes expertise in cellular therapy administration and recognition and management of potentially serious toxicities.
Successful trial execution is much more than the clinical team; research coordinators, regulatory specialists, contracting personnel, pharmacists, nursing staff and institutional leadership are all key players. The amount of coordination and administrative work can quickly get overwhelming, particularly in a resource-limited setting. One of my biggest lessons has been the importance of engaging key stakeholders early, understanding operational requirements far beyond what rheumatology training offers, and establishing clear communication pathways.
Ethical responsibility and ensuring equitable access are other key considerations. The importance of communicating uncertainties regarding the durability of response to these therapies, short- and long-term safety and potential late adverse effects cannot be overstated. As a now-Louisianian, I would be remiss not to emphasize the importance of equity and access to care. Even when a clinical trial is available locally, participation may be challenging for families due to travel distance, economic barriers, caregiver responsibilities, and health literacy. Addressing these barriers needs a deep understanding of the population we serve, intentional and compassionate planning and empathetic execution.
As pediatric rheumatologists, we are entering an exciting therapeutic era. CAR based therapies offer a glimpse of hope for children with severe, refractory autoimmune diseases. However, translating this novel scientific innovation into meaningful and safe clinical impact will depend on our collective ability to build collaborative partnerships that extend beyond rheumatology. We must consider introducing the next generation of pediatric rheumatologists to this evolving landscape by incorporating exposure to cellular therapies into training programs. My personal experience is an example that being a small pediatric rheumatology program does not mean we remain of the sidelines of scientific discovery. With the right partnerships, support and a shared purpose of serving our population, we bring these advances closer to the children that need them the most. The true measure of progress here is not simply what these therapies can achieve but whether we can ensure that the children who stand to benefit from these have the opportunity to receive them!

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.